262 related articles for article (PubMed ID: 20006922)
21. Glomerular expression of nephrin and synaptopodin, but not podocin, is decreased in kidney sections from women with preeclampsia.
Garovic VD; Wagner SJ; Petrovic LM; Gray CE; Hall P; Sugimoto H; Kalluri R; Grande JP
Nephrol Dial Transplant; 2007 Apr; 22(4):1136-43. PubMed ID: 17255128
[TBL] [Abstract][Full Text] [Related]
22. Everolimus inhibits glomerular endothelial cell proliferation and VEGF, but not long-term recovery in experimental thrombotic microangiopathy.
Keller K; Daniel C; Schöcklmann H; Endlich KH; Kerjaschki D; Johnson RJ; Hugo C
Nephrol Dial Transplant; 2006 Oct; 21(10):2724-35. PubMed ID: 16861242
[TBL] [Abstract][Full Text] [Related]
23. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
[TBL] [Abstract][Full Text] [Related]
24. VEGF-VEGFR2 inhibitor-associated hyaline occlusive glomerular microangiopathy: a Japanese single-center experience.
Ozawa M; Ohtani H; Komatsuda A; Wakui H; Takahashi N
Clin Exp Nephrol; 2021 Nov; 25(11):1193-1202. PubMed ID: 34115234
[TBL] [Abstract][Full Text] [Related]
25. Is the toxicity of anti-angiogenic drugs predictive of outcome? A review of hypertension and proteinuria as biomarkers of response to anti-angiogenic therapy.
Horsley L; Marti K; Jayson GC
Expert Opin Drug Metab Toxicol; 2012 Mar; 8(3):283-93. PubMed ID: 22283844
[TBL] [Abstract][Full Text] [Related]
26. Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?
van Heeckeren WJ; Ortiz J; Cooney MM; Remick SC
J Clin Oncol; 2007 Jul; 25(21):2993-5. PubMed ID: 17634476
[No Abstract] [Full Text] [Related]
27. Vascular endothelial growth factor trap in non small cell lung cancer.
Riely GJ; Miller VA
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4623-7. PubMed ID: 17671153
[TBL] [Abstract][Full Text] [Related]
28. Crim1KST264/KST264 mice implicate Crim1 in the regulation of vascular endothelial growth factor-A activity during glomerular vascular development.
Wilkinson L; Gilbert T; Kinna G; Ruta LA; Pennisi D; Kett M; Little MH
J Am Soc Nephrol; 2007 Jun; 18(6):1697-708. PubMed ID: 17460146
[TBL] [Abstract][Full Text] [Related]
29. Podocyte-specific expression of angiopoietin-2 causes proteinuria and apoptosis of glomerular endothelia.
Davis B; Dei Cas A; Long DA; White KE; Hayward A; Ku CH; Woolf AS; Bilous R; Viberti G; Gnudi L
J Am Soc Nephrol; 2007 Aug; 18(8):2320-9. PubMed ID: 17625119
[TBL] [Abstract][Full Text] [Related]
30. The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat.
Vogelbacher R; Wittmann S; Braun A; Daniel C; Hugo C
Transplantation; 2007 Dec; 84(11):1492-9. PubMed ID: 18091526
[TBL] [Abstract][Full Text] [Related]
31. Inducible nitric oxide synthase-derived nitric oxide promotes glomerular angiogenesis via upregulation of vascular endothelial growth factor receptors.
Ostendorf T; Van Roeyen C; Westenfeld R; Gawlik A; Kitahara M; De Heer E; Kerjaschki D; Floege J; Ketteler M
J Am Soc Nephrol; 2004 Sep; 15(9):2307-19. PubMed ID: 15339980
[TBL] [Abstract][Full Text] [Related]
32. Sam68-like mammalian protein 2, identified by digital differential display as expressed by podocytes, is induced in proteinuria and involved in splice site selection of vascular endothelial growth factor.
Cohen CD; Doran PP; Blattner SM; Merkle M; Wang GQ; Schmid H; Mathieson PW; Saleem MA; Henger A; Rastaldi MP; Kretzler M
J Am Soc Nephrol; 2005 Jul; 16(7):1958-65. PubMed ID: 15901763
[TBL] [Abstract][Full Text] [Related]
33. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
34. Mechanism of hypertension and proteinuria during angiogenesis inhibition: evolving role of endothelin-1.
Lankhorst S; Kappers MH; van Esch JH; Danser AH; van den Meiracker AH
J Hypertens; 2013 Mar; 31(3):444-54; discussion 454. PubMed ID: 23221987
[TBL] [Abstract][Full Text] [Related]
35. All anti-vascular endothelial growth factor drugs can induce 'pre-eclampsia-like syndrome': a RARe study.
Vigneau C; Lorcy N; Dolley-Hitze T; Jouan F; Arlot-Bonnemains Y; Laguerre B; Verhoest G; Goujon JM; Belaud-Rotureau MA; Rioux-Leclercq N
Nephrol Dial Transplant; 2014 Feb; 29(2):325-32. PubMed ID: 24302609
[TBL] [Abstract][Full Text] [Related]
36. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.
Tabernero J
Mol Cancer Res; 2007 Mar; 5(3):203-20. PubMed ID: 17374728
[TBL] [Abstract][Full Text] [Related]
37. Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms.
Mulders P
BJU Int; 2009 Dec; 104(11):1585-9. PubMed ID: 20053190
[TBL] [Abstract][Full Text] [Related]
38. [Anticancer drugs under pressure].
Ben Aïssa A; George AC; El M'Rabet FZ; Mach N; Dietrich PY; Pechère-Bertschi A
Rev Med Suisse; 2011 Sep; 7(308):1761-6. PubMed ID: 21954818
[TBL] [Abstract][Full Text] [Related]
39. Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma.
Roncone D; Satoskar A; Nadasdy T; Monk JP; Rovin BH
Nat Clin Pract Nephrol; 2007 May; 3(5):287-93. PubMed ID: 17457362
[TBL] [Abstract][Full Text] [Related]
40. [Renovascular effects of antiangiogenic drugs].
Deray G; Janus N; Aloy B; Launay-Vacher V
Bull Cancer; 2016; 103(7-8):662-6. PubMed ID: 27318610
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
